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ABSTRACT: 
A computational study was performed to better understand the differences 
between human arylamine N-acetyltransferase (NAT) 1 and 2.  Homology models were 
constructed from available crystal structures and comparisons of the active site residues 
125, 127, and 129 for these two enzymes provide insight into observed substrate 
differences.  The NAT2 model provided a basis for understanding how some of the 
common mutations may affect the structure of the protein.  Molecular dynamics 
simulations of the human NAT models and the template structure (NAT from 
Mycobacterium smegmatis) were performed and showed the models to be stable and 
reasonable.  Docking studies of hydroxylated heterocyclic amines in the models of NAT1 
and NAT2 probed the differences exhibited by these two proteins with mutagenic agents.  
The hydroxylated heterocyclic amines were only able to fit into the NAT2 active site, and 
an alternative binding site by the P-loop was found using our models and will be 
discussed.  Additionally, quantum mechanical calculations were performed to study the 
O-acetylation reaction of the hydroxylated heterocyclic amines N-OH MeIQx and N-OH 
PhIP.  This study has given us insight into why there are substrate differences among 
isoenzymes and explains some of the polymorphic activity differences. 
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INTRODUCTION: 
Arylamine N-acetyltransferase (NAT) was discovered to be the enzyme 
responsible for inactivation of the antitubercular drug isoniazid1 by transfer of an acetyl 
group from acetyl coenzyme A (acetyl-CoA) to the amine group in isoniazid and plays an 
important role in the detoxification of xenobiotics.2 These cytosolic enzymes are present 
in eukaryotes and prokaryotes.3 Humans have two isoenzymes of arylamine N-
acetyltransferases (NAT1 and NAT2) that are 81% homologous but differ in their tissue 
distribution and substrate specificity. Although NAT enzymes can detoxify molecules by 
N-acetylation, they can also activate other molecules through O-acetylation to form 
reactive acetoxy-esters that are unstable and decompose to electrophiles that bind to DNA 
leading to mutagenesis and carcinogenesis.2 Polymorphisms in NAT enzymes result in 
differences in acetylation rate (slow and rapid) and can occur more commonly in certain 
ethnic populations.4,5 The Gly191Ala mutant in NAT2 is more commonly seen in the 
African population, but the Gly268Glu is more commonly seen in Asians. Slow 
acetylation rates may make individuals more susceptible to certain diseases, and there are 
numerous studies that indicate a relationship between the NAT polymorphisms and 
certain kinds of cancers.6,7 Slow NAT2 acetylation phenotypes have shown a relationship 
to urinary bladder cancer.8 NAT polymorphisms linked to colon, breast, lung, and 
prostate cancers are more controversial.9 
Crystal structures of four NATs show these enzymes are related to cysteine 
proteases and contain a catalytic triad of Cys-His-Asp that carries out the acetylation 
reaction.10-13 The overall structures of these four NATs are very similar, and they can be 
easily overlaid.  The catalytic triad is strictly conserved in NATs, and mutation of these 
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residues has shown that all three are necessary for catalysis; Asp is likely important for 
correct positioning of the residues rather than participates in the reaction.14-17 The enzyme 
follows a ping-pong bi-bi mechanism that has the acetyl-CoA binding to NAT and 
transferring the acetyl group to the catalytic cysteine followed by acetylation of the 
substrate.18 Although this reaction is a two-step process, substrates can bind to NAT in 
the absence of acetyl-CoA or an acetylated enzyme. NMR and crystallography have 
shown that isoniazid is able to bind to bacterial NATs in the absence of an acetylated 
NAT.19,20  To better understand the differences in substrate specificity and the effect of 
polymorphisms in human NAT1 and NAT2, the molecular structures need to be 
characterized.  Though the human X-ray structures for either NAT is not yet available, 
the recently solved crystal structure of NAT from Mycobacterium smegmatis11 allowed 
us to build homology models of the full-length proteins of human NAT1 and NAT2.  
Previous homology models for human NAT1 and NAT2 were not of the complete 
enzymes, they consisted of only the first ~100 residues out of 290 residues for the NAT 
enzymes.21,22 These models of human arylamine N-acetyltransferases provided insight 
into the differences in substrate specificity between the isoenzymes and the activity 
differences in some of the observed polymorphisms.  
 
METHOD: 
Multiple sequence alignment: 
The amino acid sequence of human NAT1 (hNAT1) and NAT2 (hNAT2) is 32% 
and 29% identical to the NAT from Mycobacterium smegmatis (msNAT), respectively, a 
level of homology that suggests that their three-dimensional structures will be quite 
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similar as well.  The sequence alignment between these two proteins to the template was 
straightforward, except for a few regions of lower homology (Figure 1).  Since the 
correctness of the sequence-structure alignment is the major determinant of the model 
quality,23 special attention was paid to the alignment in these low homology regions.  To 
determine which regions needed further analysis PSI-BLAST-ISS was applied, an 
intermediate sequence search procedure, described in more detail elsewhere.24  Briefly, a 
set of sequences having some level of homology to both human NAT (hNAT1 or 
hNAT2) and msNAT proteins were used as seeds to generate corresponding PSI-
BLAST25 profiles.  Using the SEALS package26 and in-house Perl scripts, alignments 
between these two sequences were extracted from the resulting individual PSI-BLAST 
profiles and compared.  The convergence of the alignment between the human NAT’s 
and msNAT sequences in a particular region was then used as an indicator of the 
alignment reliability in this region.     
 
 Model Building: 
 Three-dimensional models were generated automatically from the alignments 
described above with MODELLER.27  There are large insertions of residues at positions 
170-186 and 248-252 for both human NATs relative to msNAT.  The initial models for 
hNAT1 and hNAT2 were created with the msNAT crystal structure (1GX3).11 To 
accommodate the insertion at residues 170-186, residues 168-175 in the msNAT crystal 
structure were removed from the template structure. Residue side-chains for the resulting 
models were positioned using a backbone-dependent rotamer library implemented in 
SCWRL.28  The molecular mechanics program AMBER29 was used to further refine the 
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models.  A force constant of 25 kcal/mole•Å2 was placed on all atoms, and constrained 
energy minimization was performed using 250 steps of steepest descents and 750 steps of 
conjugate gradients to remove unfavorable contacts and improve bond lengths and 
angles.  The quality of the models was evaluated using PROCHECK30 and ProsaII.31 
 
 Molecular Dynamics Simulations: 
 Molecular dynamics (MD) was performed on each model of the human NAT and 
the crystal structure of msNAT (1GX3, used as a control).  The simulations were 
performed with AMBER using the Cornell force field.32  The catalytic cysteine and 
histidine in each NAT molecule was modeled as charged residues.  NMR studies of the 
cysteine protease papain have shown the analogous residues are ionized in the ground 
state.33,34  Each NAT molecule was solvated in a box of TIP3P35 water sufficient in size 
to have at least 10 Å of water between the protein and the solvent interface (~81 × 81 × 
81 Å3 initial box size).  The active site residues Cys68 and His107 were simulated as 
ionized residues.15,33,34 To neutralize the systems 7 sodium ions were added to the 
msNAT simulation, 4 sodium ions to the hNAT1, and 6 sodium ions to hNAT2.  The 
systems consisted of about 63,000 atoms (~19,000 water molecules).  Each system was 
energy minimized using 500 steps of steepest descent and 1500 steps of conjugate 
gradient.  Constant temperature and pressure dynamics (NPT) were performed on these 
minimized systems.  Periodic boundary conditions were used, and electrostatic 
interactions were treated by particle mesh Ewald methods36 with a 9 Å cutoff in direct 
space and using a 1 Å grid.  Bonds containing a hydrogen were constrained using 
SHAKE,37 and a time step of 2 fs was used in each simulation.  The systems were 
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initially coupled to a heat bath at 100 K for the first 20 ps.  The heat bath temperature was 
increased to 200 K for the next 10 ps and finally raised to 300 K for the remainder of the 
simulation.  Coupling constants of 5 and 2 ps were used for enzyme and solvent, 
respectively.  Each simulation was performed for a total of 1 ns, and the last 500 ps were 
used for analysis.  The atomic fluctuations obtained from the simulations can be 
compared to the crystallographic results by converting the Debye-Waller (B-) factors to 
mean squared fluctuations using the equation <Δr> = (3B/8π2)½. 
 
Docking Simulations: 
 The activated heterocyclic amines N-hydroxyl-2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (N-OH PhIP), and N-hydroxyl-2-amino-3,8-
dimethylimidazo[4,5-f]quinoxaline (N-OH MeIQx) were docked into the active sites of 
the NAT models from clustering the coordinate set from molecular dynamics using the 
program Autodock 3.05.38  The initial geometries of the ligands were optimized at the 
HF/6-31G(d) level of theory using the program Gaussian98.39  The partial atomic charges 
for the ligands were obtained by the RESP method.40  Kollman-united atom charges were 
used for the NAT models.41  A 60 × 60 × 60 grid was used for docking all the ligands 
with a spacing of 0.375 Å. The grids were centered above the catalytic histidine (His107).  
A Lamarckian algorithm was used to generate conformations for the ligands with the 
active site.38  The parameters used for the Lamarckian genetic algorithm were the same as 
in Legge et. al. except the maximum number of energy evaluations was 150,000.42  A 
total of 500 conformers were generated for a ligand in each NAT active site.  The 
conformers were clustered using a 0.5 Å RMSD.   
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Ab initio calculations: 
 The acetylation reaction of N-OH PhIP and N-OH MeIQx with the thioester S-
methyl thioacetate was studied by density functional theory calculations.  All calculations 
were performed using the program Gaussian98 or Gaussian03.39,43  The geometries were 
optimized using density functional theory (DFT) at the B3LYP/6-31G(d) level of 
theory.44,45  Harmonic frequency calculations were performed to ensure the structures 
were minima and transition states.  The zero point energies from the frequency 
calculations were scaled by 0.98.  The energies of each structure from single point 
calculations at the B3LYP/6-311+G(d,p) level of theory using the optimized geometry 
(B3LYP/6-311+G(d,p)//B3LYP/6-31G(d)).  
 
RESULTS AND DISCUSSION: 
Analysis of NAT models: 
 Although hNAT1 and hNAT2 share 81% sequence similarity and utilize the same 
reaction mechanism for acetylation of substrates, there are significant differences in these 
two enzymes such as tissue distribution, substrate specificity, and expression levels 
during development. The substrate specificity of these two enzymes is different. Human 
NAT2 has the ability to acetylate larger molecules and appears responsible for activating 
hydroxylated heterocyclic aromatic molecules. Human NAT1 has lower activity than 
hNAT2 and is not as well studied as hNAT2. The overall fold of the arylamine N-
acetyltransferases appears to be robust. So far, four bacterial NAT crystal structures have 
been solved for this family of enzymes, and the overall structures and the positioning of 
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the catalytic triads are very similar even though the homology is only ~25% between 
these NAT enzymes.  
Both human NATs contain two significant insertions relative to the bacterial 
NATs (Figure 1). A long 17 residue insertion is present between α-helix 6 and β-sheet 5. 
A smaller insertion of 5 residues is at the end of a β-sheet. The larger insertion is distant 
from the active site, but the smaller insertion is adjacent to the catalytic triad, and both do 
not affect the positioning of the catalytic residues in either model (Figure 2). The large 
insertion was modeled as a loop. Structure prediction servers (PsiPred46, Jpred47, and 
SCRATCH48) assigned a small portion of the sequence to be β-sheet with the rest of this 
insertion sequence a coil. This insertion sequence was not found to be homologous with 
any sequence of a solved crystal structure. Recently, Josephy and coworkers have created 
models for the human NATs, and this region was also modeled as an extended loop.49 
The quality of our models was evaluated using ProsaII and Procheck. ProsaII scores for 
hNAT1 and hNAT2 were –7.99 and –7.58, respectively (a lower value indicates a more 
reasonable structure). The ProsaII score for the template structure (1GX3) was –10.67. 
Procheck G-scores for hNAT1 and hNAT2 were 0.03 and –0.07, respectively. Procheck 
G-scores above –0.5 imply a reasonable structure, and a higher G-score indicates a more 
reasonable structure. The hNAT1 had 88.5% of the residues in the most favorable regions 
of the Ramachandran map, and hNAT2 had a slightly lower value of 84.4%. The 
template structure had 88.3% of residues in the most favored regions. The sequence 
alignment used for these models and the one used by Josephy and coworkers are similar. 
Comparison of our sequence alignment with the sequence alignment by Josephy and 
coworkers shows that the small insertions or deletions (one to two residues) are modeled 
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within 3 residues of each other.  The 17 residue insertion in both human NATs were 
modeled in the identical position. The only significant difference is a modeled insertion 
of 5 residues into the third domain of msNAT in our sequence alignment. This region of 
the enzyme was the most difficult to model and may explain the slight difference in 
Procheck G-scores between our models and the ones created by Josephy and coworkers (-
0.21 for both human NAT models). 
 The active sites for the human NATs and the msNAT are similar with the 
catalytic triad of Cys-His-Asp positioned within an alpha and beta fold (a single α-helix 
with a 3 stranded β-sheet). The hNAT1 model shows that Phe125 is in close proximity to 
the catalytic triad, and having serine at this position in hNAT2 opens up the area (Figure 
3). This change in residue has a smaller than expected effect because there is a 
phenylalanine at the opposite position of residue Phe125 in hNAT2 (Phe93, the 
analogous residue in hNAT1 is valine) that takes up some of the space vacated by a 
phenylalanine. Mutation experiments have shown that Phe125 in hNAT1 is an important 
residue in determining substrate specificity.50 
 Human NAT1 and NAT2 have different substrate specificity. Site-directed 
mutagenesis studies have shown that residues 125, 127, and 129 are important 
determinants in the specificity of human NATs.50 In hNAT1, these residues are Phe125, 
Arg127, and Tyr129, and in hNAT2 all three of these residues are serines. The models of 
the human NATs show these residues are in close proximity to the catalytic triad, and it is 
readily apparent why p-aminosalicylic acid (PAS) is specific to hNAT1. The carboxylate 
group on PAS can form a salt bridge with the guanidinium group of Arg127, and site 
directed mutagenesis shows that changing this arginine to serine drastically affects the 
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binding constant. Mutation of Phe125 or Tyr129 has only a minor effect on the binding 
constant of PAS to hNAT1. Human NAT2 prefers larger molecules than hNAT1. 
Inspection of the molecular surfaces of these proteins provides insight into their 
specificity. Phe125, Arg127, and Tyr129 are positioned above the catalytic Cys68 and 
His107 in hNAT1 and act to restrict the length of the substrates that can bind to this 
enzyme (Figure 4). In hNAT2, having serine at residues 125, 127, and 129 provides more 
space in the active site allowing larger (longer) substrates to be accommodated such as 
sulphamethazine (SMZ). Individual mutations of these serines did not greatly change the 
binding constant of SMZ, but the double mutant of Ser127Arg and Ser129Tyr greatly 
increased the binding constant of SMZ. These two residues are directly above Cys68 and 
His107 in hNAT2, and mutating the serines to the larger phenylalanine and arginine 
likely interferes with SMZ fitting into the active site. Interestingly, the single mutation of 
Ser129 to tyrosine in hNAT2 lowered the binding constant for PAS more than the Ser127 
to arginine mutation.  
Polymorphisms in human NATs affect the rate of acetylation of substrates and are 
divided into slow and rapid phenotypes. Eleven single nucleotide polymorphisms in 
hNAT2 lead to six different amino acid mutations in the enzyme; Arg64Gln, Ile114Thr, 
Glu145Pro, Arg197Gln, Lys282Thr, and Gly286Thr.  None of these mutations occurs in 
the active site of hNAT2 and are more likely to affect the stability of the enzyme rather 
than the acetylation reaction (Figure 5). As seen previously in a truncated homology 
model of hNAT2,22 Arg64 forms an internal salt bridge with Glu38 providing structural 
stability for hNAT2. In addition to the salt bridge, the sidechain of Arg64 also forms a 
hydrogen bond with Asn41. Mutation of Arg64 to glutamine would remove the salt 
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bridge and destabilize this region of the protein. Ile114 resides in a cluster of 
hydrophobic residues such as Ile21, Val24, Phe84, Val112, and Tyr119, and mutation of 
this residue into a polar threonine could cause this residue to reorient and disrupt the 
hydrophobic cluster. Glu145 is located in a β-sheet; mutation of this residue to a proline 
would likely redirect the backbone and disrupt the secondary structure. The effect on the 
protein structure on mutating Arg197 to a glutamate is more difficult to determine. This 
residue is on the surface of the protein and distant from the active site. The effect of 
mutating Gly286 to a threonine is not obvious since this residue resides on the surface of 
the protein and close to the C-terminus. Truncation of the C-terminus of NAT from 
Salmonella typhimurium by 11 residues does impair binding of acetyl-CoA and substrate 
binding.51  Mutation of the Gly286 may affect the acetylation reaction rather than affect 
the three-dimensional structure.  A truncated version of hNAT1 (containing the first 204 
amino-terminal residues) is able to form the acetylated intermediate but is unable to 
transfer the acetyl group to substrate.52  
 
Molecular dynamics Simulations: 
Molecular dynamics simulations were performed on both human NAT models 
and the msNAT (for comparison). All proteins were stable for the duration of the 
simulations. The msNAT simulation had a root mean squared deviation (RMSD) of ~1.4 
Å for the backbone atoms relative to the starting structure. The models had higher 
RMSDs of 2.0 Å and 2.4 Å for hNAT1 and hNAT2, respectively. The major contribution 
to the RMSD for the NAT models were due to changes in conformation of the generated 
loop insertions at residues 170-186 and residues 248-252, but the changes in 
 13 
conformation did not affect the overall structure of the proteins.  Comparison of the root 
mean squared fluctuations (RMSF) of the backbone atoms of msNAT from molecular 
dynamics is in good agreement with RMSF estimated from the crystallographic B-factors 
(Figure 6).  The RMSF for hNAT1 and hNAT2 are very similar to those observed for 
msNAT except at the residue insertions.  These areas show large scale fluctuations which 
is not surprising since the coordinates were built-in rather than based on positions within 
the template.  The C-terminus of hNAT2 also exhibits large scale fluctuations.  This is 
due to the region containing two prolines causing the area to be unstructured.  In hNAT1, 
the C-terminus was modeled with an α-helix in this region which is similar to msNAT.  
The catalytic triad in both human NAT models is stable through out the simulations.  The 
sulfur of Cys68 forms a hydrogen bond with HD1 of His107, 2.01 ± 0.09 Å and 2.03 ± 
0.09 Å for hNAT1 and hNAT2, respectively.  The HE2 of His107 forms a hydrogen bond 
with one of the carboxylate oxygens of Asp122, 1.77 ± 0.10 Å and 1.93 ± 0.21 Å for 
hNAT1 and hNAT2, respectively.  The results from the solvated molecular dynamics 
simulations show that the models for human NATs are stable in the nanosecond time 
scale and likely do not contain gross errors. 
 
Heterocyclic Amine Docking: 
The initial structures for hNAT1 and hNAT2 along with coordinates from the 
molecular dynamics simulations were used for docking studies on the orientational 
preferences of N-OH MeIQx and N-OH PhIP.  Neither activated heterocyclic amine 
could be docked into the active site of hNAT1 for any of the coordinate sets.  Both 
compounds were docked either on the exterior of the protein or in a pocket close to the P-
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loop (residues 126, 127, 128, and 129) but distant from the active site.  During dynamics, 
the P-loop in hNAT1 undergoes a conformational change that widens a pocket that 
allows binding of these heterocyclic amines.  The residues Ile32, Gly126, Arg127, 
Ser128, Tyr129, Gln130, Ser224, Leu225, and Gln226 form this pocket.  These results 
are consistent with mutagenesis data that shows hNAT1 is virtually unable to O-acetylate 
heterocyclic amines.  Docking of N-OH PhIP and N-OH MeIQx to hNAT2 showed that 
both molecules could fit into the active site of the enzyme with similar conformations 
(Figure 7). The docked conformation of N-OH MeIQx is similar to the positioning of IQ 
in hNAT2 obtained by Josephy and coworkers.49 These heterocyclic amine compounds 
interact with residues Phe37, Trp67, Phe93, Gly124, Ser125, Leu209, Ser216, and 
Phe217 in hNAT2. As can be seen from these residues, the binding site for hNAT2 is 
primarily hydrophobic. Interestingly, the crystal structure of msNAT with isoniazid has 
the aromatic group of the drug approximately 90° relative to both N-OH compounds. The 
active site of msNAT is smaller than hNAT2 because of Phe130 in msNAT occupies the 
analogous position of Ser125 in hNAT2, and isoniazid is able to form a π-stacking 
interaction with Phe130. The positioning of the aromatic groups of the N-OH compounds 
is similar to placement of bound p-bromoacetanilide inhibitor in stNAT. Although many 
conformers were docked into the active site, there was also another site on hNAT2 that 
was highly populated; and the energies were comparable to ones obtained in the active 
site.  This alternate binding site is similar in position to one found in docking simulations 
by Sim and coworkers when they docked aromatic compounds to the active site of the 
NAT from Salmonella typhimurium.51 Josephy and coworkers have shown that 
mutagenic activation of PhIP in Salmonella is not promoted by hNAT2, but MeIQx 
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genotoxcity is linked to hNAT2 activation.53  These docking results are not consistent 
with this result because both molecules are able to bind in the active site of hNAT2.  
Although both molecules bind in the active site, their chemistries for O-acetylation may 
differ.  This possibility was also investigated by calculating the reaction pathway for O-
acetylation. 
 
Ab initio Calculations of O-Acetylation Reaction Pathway: 
The O-acetylation reaction of N-OH PhIP and N-OH MeIQx with S-methyl 
thioacetate was studied by ab initio calculations. Although these calculations are 
performed in the gas-phase, they should be relevant for these enzymes since the active 
site of NATs are hydrophobic and not easily accessible to solvent. To our knowledge the 
pKas of N-OH PhIP and N-OH MeIQx have not been published; thus the O-acetylation 
reactions were calculated for N-OH MeIQx and N-OH PhIP and for both compounds 
deprotonated (N-O−).  In the case of the reaction with the N-OH group, a reactant 
complex is formed between S-methyl thioacetate and either N-OH PhIP or N-OH MeIQx 
that is structurally similar, and both complexes are approximately -4.0 kcal/mole more 
stable than their respective separated reactants (Figure 8).  The hydrogen of the N-OH 
group forms a hydrogen bond with the sulfur of the thioester (2.511 Å and 2.487 Å for N-
OH MeIQx and N-OH PhIP, respectively), and the oxygen of the N-OH group is ~4.0 Å 
from the carbonyl carbon of the thioester.  The distance from the oxygen of the N-OH to 
the carbonyl carbon is much shorter when the transition state is formed (1.962 Å and 
1.980 Å for N-OH MeIQx and N-OH PhIP, respectively).  The transition state is tight 
with significant O-C bond formation.  The hydrogen of the N-OH group is shared 
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between the oxygen (1.397 Å) and the sulfur of the thioester (1.528 Å) for N-OH MeIQx.  
Similar distances were obtained for the transition state structure of N-OH PhIP.  The 
transition state undergoes a concerted transfer of the hydrogen from the N-OH group to 
the sulfur of S-methyl thioacetate and bond formation between the oxygen of the N-OH 
group with the carbonyl.  The activation barrier for this reaction is 37.84 and 37.25 
kcal/mole for N-OH MeIQx and N-OH PhIP, respectively.  The transition state decays to 
the products, methylthiol and N-acetyl compounds.  The O-acetylation reaction of N-OH 
MeIQx or N-OH PhIP with S-methyl thioacetate has very similar geometries and relative 
energies.  Given the high activation barrier for this reaction, it is unlikely that NAT 
would utilize this reaction pathway to O-acetylate N-OH compounds. 
 Since the O-acetylation reaction with an N-OH group is unlikely to occur because 
of the high activation barrier, the O-acetylation reaction with a deprotonated N-OH group 
(denoted N-O−) was investigated.  An ion-molecule complex is first formed that is 
approximately –9.0 kcal/mole more stable than the separated reactants (Figure 9).  The 
thioester and N-O− MeIQx are almost parallel to each other in the ion-molecule complex.  
The oxygen of the N-O− is 3.493 Å from the carbonyl carbon of the thioester.  
Additionally, a hydrogen bond is formed between the carbonyl oxygen of the thioester 
and the hydrogen on the nitrogen of the N-O− (2.524 Å).  This structure proceeds to a 
transition state that is looser than obtained for the protonated reaction.  The oxygen to 
carbonyl carbon distance is 2.905 Å, and the hydrogen to carbonyl oxygen distance 
shortens to 2.140 Å.  The relative geometry of these two molecules is different from that 
observed for the ion-molecule complex.  Whereas the ion-molecule complex had the 
molecules parallel, the transition state has the N-O− MeIQx almost at a 90° angle relative 
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to the thioester.  The activation barrier for this step is only 1.14 kcal/mole.  After this 
transition state, a tetrahedral intermediate is formed.  The carbonyl oxygen-carbon bond 
is formed (1.576 Å), and the carbonyl carbon-sulfur bond elongates to 1.993 Å.  The 
tetrahedral intermediate is –1.76 kcal/mole more stable than the first transition state.  A 
second transition state is formed after the tetrahedral intermediate.  There is a slight 
shortening of the oxygen-carbonyl carbon bond to 1.539 Å, and the carbonyl carbon-
sulfur bond lengthens to 2.090 Å.  The activation barrier to the second transition state is 
slight at 0.43 kcal/mole.  Once past the second transition state, the energy steeply falls to 
form the products N-acetyl MeIQx and CH3S−.  The product complex is –17.26 kcal/mole 
more stabile than the second transition state (Figure 10). This reaction pathway is 
analogous to amide hydrolysis catalyzed by cysteine proteases.54 
The O-acetylation reaction with N-O− PhIP and S-methyl thioacetate has similar 
optimized structures as N-O− MeIQx along the reaction pathway initially, but when the 
zero-point energies are taken into account, the tetrahedral intermediate is higher in energy 
than the first transition state leading to a single energy barrier separating the reactants 
from the products.  The transition state structure for this reaction is similar to the second 
transition state structure in the reaction with N-O− MeIQx.  The activation barrier for the 
N-O− PhIP O-acetylation reaction is a modest 4.43 kcal/mole.  Although this activation 
barrier is greater than the one calculated for N-O− MeIQx, it is not high enough to 
significantly impede the O-acetylation reaction.  These calculations imply that if an N-O− 
compound is able to bind in the active site of hNAT2, then the reaction will go rapidly to 
completion, but if an N-OH compound is in the active site, then the O-acetylation 
reaction will not occur in a reasonable amount of time.  A possible explanation of the 
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results is N-OH compounds bind to NAT but do not react until deprotonation of the 
hydroxyl group occurs by a general base within the active site.  The histidine (His107) of 
the catalytic triad could be the general base for the reaction. Experimental measurements 
on the hamster NAT2 puts the apparent pKa of the catalytic histidine to be around 5.5 for 
the acetylated enzyme but greater than 9.0 when involved in a thiolate-imidazolium 
pair.15,16  An estimated pKa for deprotonation of the hydroxyl group for N-OH PhIP 
(9.81) and N-OH MeIQx (9.77) was obtained using the SPARC server55 and imply the 
reactivity of N-OH PhIP and N-OH MeIQx are similar. The proposed catalytic 
mechanism for deacetylation of hamster NAT2, similar to human NAT1, is dominated by 
the nucleophilicity of the substrate and assisted by a general base which is consistent with 
these ab initio calculations.  It has been shown in vitro that N-OH PhIP and N-OH 
MeIQx formed DNA adducts, identified as dG-C8-PhIP and dG-C8-MeIQx, respectively, 
with intact prostate epithelial cells prepared from benign prostatic hypertrophy tissues 
known to contain hNAT2.56  In the same study, repair synthesis of cells was observed 
when treated with N-OH PhIP and N-OH MeIQx but not with the parent compounds or 
their nitro derivatives.  Our results do not explain the observed difference in mutagenic 
activity of PhIP relative to MeIQx in Salmonella typhimurium containing both human 
NAT enzymes.  This may point to differences in reactivity or interactions of these 
compounds further upstream in DNA adduct formation in Salmonella. 
 
CONCLUSIONS: 
 Three-dimensional structures for human NAT1 and NAT2 were constructed from 
coordinates of the NAT from Mycobacterium smegmatis.  The modeled structures are 
 19 
very similar to the template structure, although both human NATs contain a long coil 
insertion. The hNAT2 model is useful in rationalizing the effect of some polymorphisms 
on the protein structure. Molecular dynamics simulations of the models show that they 
are stable in solution on the nanosecond time scale.  Docking of N-OH heterocyclic 
amines was possible in the active site of hNAT2, but the active site of hNAT1 is too 
small to accommodate these compounds.  A second site in hNAT2 close to the P-loop 
and to the active site was also able to accommodate these N-OH heterocyclic amines and 
maybe the adenine of acetyl-CoA binding site.  Ab initio calculations of model 
compounds show that the N-OH group is insufficient to cause O-acetylation with S-
methyl thioacetate. A very high activation barrier separates the reactions and products.  If 
the N-OH group is deprotonated, possibly general base catalyzed, the O-acetylation 
reaction is facile.  These results are consistent with in vitro experiments of N-OH PhIP 
and N-OH MeIQx with prostate epithelial cells that show DNA adducts are formed with 
both compounds. 
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Figure Legends: 
 
Figure 1:  Sequence alignment of human NAT1 (hNAT1) and NAT2 (hNAT2) with NAT 
from Mycobacterium smegmatis (msNAT). 
 
Figure 2:  Overlay of the modeled structures of hNAT1 and hNAT2. The catalytic triads 
of Cys-His-Asp of the two enzymes are in identical positions. Panel B is a 90º 
rotated view of Panel A. 
 
Figure 3:  Active site of hNAT1 showing the relative positioning of the catalytic residues 
relative to residues Phe125 (cyan), Arg127 (red), and Tyr129 (magenta) which are 
important for substrate specificity. 
 
Figure 4:  Molecular surface representation of hNAT1 (red) and hNAT2 (green). The 
catalytic cysteine is colored yellow. Only in hNAT2 is cysteine visible on the 
molecular surface of the enzyme. 
 
Figure 5:  Locations of polymorphisms in hNAT2: (A) Gly286Thr, (B) Gln145Pro, (C) 
Arg64Gln, and (D) Ile114Thr. Structures inside the boxes show a more detailed 
representation of the local environment around the mutated residue, colored green 
in panels (B) and (D). 
 
Figure 6:  Root mean squared fluctuations (RMSF) for msNAT (Panel A) from 
crystallography (red) and simulation (green). RMSF of hNAT1 (blue) and hNAT2 
(violet) from simulations are shown in Panel B. 
 
Figure 7:  Docked conformations of N-OH MeIQx and N-OH PhIP in the active site of 
hNAT2 (Panel B). Panel C shows the two binding sites for N-HO PhIP found 
from the docking. The positioning of the second molecule is in close contact with 
the P-loop that maybe important for binding the adenine of acetyl-CoA. 
 
Figure 8:  Structures obtained from DFT calculations for the O-acetylation reaction 
between N-OH MeIQx and S-methyl thioacetate. Distances are in angstroms. 
 
Figure 9:  Structures obtained from DFT calculations for the O-acetylation reaction 
between N-O− MeIQx and S-methyl thioacetate. Distances are in angstroms. 
 
Figure 10:  Reaction pathway for the O-acetylation reaction between N-O− MeIQx and S-
methyl thioacetate. Energies are in kcal/mole. 
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